MacroPore Biosurgery is actively developing treatments for patients using regenerative cell technology. Our approach is unique in that we use adipose (fat) tissue as the source of regenerative cells. Regenerative cells from adipose tissue are of three primary kinds: adult stem cells, endothelial progenitor cells and growth factor producing cells. These cells have demonstrated in preclinical research that they have the ability to repair injured tissues.

We have several research programs in stem cells; from basic research to understand the cellular events that lead to cell specialization to gene discovery to uncover growth factors that will help cure diseases and to systems to screen drugs and small chemicals.

To become the leader in stem cell based treatments of diseases characterized by damage to or degeneration of the central nervous system (CNS), liver, pancreas and other tissue.

Our lead drug candidate AV-101 targets two large CNS markets, epilepsy and neuropathic pain. Our key R and D partnership applies our clinically predictive in vitro embryonic stem cell technologies to discover and develop a new generation of drug candidates for diabetes and other Metabolic Syndrome diseases.

PrimeGen Biotech LLC is a privately-held company developing proprietary methods to regenerate the potency of adult stem cells.

Human Fetal Stem Cell Therapy is a medical treatment whereby human Fetal Stem Cells (“mother” cells of the body) are transplanted into a patient. These cellular building blocks are usually administered intravenously (Fetal pluripotent hematopoietic stem cells) and subcutaneously (Fetal neuronal stem cells). It is a painless procedure, which takes place in approximately one hour, with no negative side effects.

AllCells Limited Liability Company (LLC) is a biotechnology company dedicating to provide human cells and total RNA for scientific research in vitro only. Its products are not for clinical use in human.

NeuroGeneration develops stem cell therapy products that will have a major impact on the treatment of neurological diseases, including Parkinson’s Disease, Alzheimer’s Disease, Epilepsy, Spinal Cord injury, Stroke and MS/ALS.

Applying stem cell technology to save, restore and improve lives.

Geron is focused on developing and commercializing therapeutic and diagnostic products for cancer based on our telomerase technology, and cell-based therapeutics using our human embryonic stem cell technology.

HemaCare collects, processes and distributes human blood products to hospitals and research-related organizations. We operate donor centers and mobile donor vehicles to collect transfusable blood products from donors, and offer human-derived blood products to health research organizations. HemaCare also provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments, to patients and in connection with clinical trials.